Proving to all that hot penny stocks still exist, Propanc Health Group Corporation (OTC: PPCH) has been having a month to remember as shares have now surpassed $0.09 for gains of over 500% in less than 12 trading sessions. The emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients began its ascent just prior to the start of April despite no announcements emerging since mid-March when they announced the commencement of the second stage of its POP1 research program with the University of Jaen, Spain, to investigate further the anti-cancer effects and cellular mechanisms associated with proenzymes. With PPCH stock now leading all other penny stocks on the OTC, could $0.10 be out of the question?
Want to crush the Markets and make profits of $624, $2,897, even $40,656?
Click HERE To Make Sure You Get All Of Our Penny Stock Alerts!
PPCH Stock Quote / Chart
The big news driving this development stage company upwards all month surfaced last week when Propanc announced that it will be featured in the NY Times Sunday Magazine, under Health Essentials: Cancer Prevention & Treatment, April 19th. Regardless, it was nearly two weeks before the news announcement when PPCH shares began to run from under $0.02 as they continue to focus on identifying new, patentable drugs as back up compounds to the Company’s lead product, PRP.
Back in February, Propanc announced it was proceeding with pivotal animal studies to support its planned pre-IND meeting with the FDA, and the initiation of future licensing discussions for its lead product, PRP. The planned animal studies are designed to better understand PRP’s mode of action, how the drug is distributed and breaks down in the body, its effectiveness in inhibiting metastases and associated biological markers, as well as prolonging survival in animals, key information from a regulatory and marketing perspective.
What’s concerning though is how when you look over the most recent 8K filing from Monday, Propanc has entered into a number of financing deals and a PR deal as well with Circadian Group for which the Company issued to Circadian a 10% convertible note in the principal amount of $60,000 as compensation for services to be rendered. The Circadian Agreement bears interest at the rate of 10% per annum which must all be paid, together with the principal, on March 11, 2017. More noteworthy is the clause: “Upon the Company’s default, may be convertible into Common Stock, at the less price of $0.0175 or 75% of the volume weighted average of the three lowest trading price in the ten (10) trading days prior to such conversion.”
Despite the obvious, the PR Propanc will get form being featured in the NY Times Sunday Magazine, a feature which is expected to cover the inside story on the Company so far, developments and challenges, and plans to commercialize their technology, from the perspective of the Company’s Co-Founder and Chief Executive Officer, James Nathanielsz, is PRICELESS. With $2.8 million worth of PPCH shares exchanged yesterday and already $1.53 million today, that $0.10 target we told loyal subscribers to target two weeks ago looks to be within reach this week.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About PPCH Stock
Propanc Health Group Corporation, since inception, substantially all of the efforts of the Company have been the development of new cancer treatments targeting high risk patients who need a follow up, nontoxic, long term therapy which prevents the cancer from returning and spreading.
Level 13, Suite 1307
530 Collins Street
Melbourne, VIC 3000
Phone: 61 03 9614 2795
Issued and Outstanding: 82,444,100
Last 5 Trading Sessions:
We are 100% Anti-Spam and will never rent or sell your information.
Many of our picks go up 100%, 200%, even 10,000%, see for yourself.
[gravityform id=”6″ name=”Post” title=”false”]Share